Shots: The US FDA’s approval is based on two P-II studies (144wks. & 88wks. study) assessing Crysvita in 14 & 13 patients conducted by Ultragenyx & Kyowa Kirin in the […]readmore
Tags : Tumor-Induced Osteomalacia